Full Press Release Details
Medical Secures Patent for LIBERTY Robotic System in the United States
Mass., October 6, 2021 - Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office
(USPTO) has issued a Notice of Allowance covering the Company's LIBERTY Robotic System. Globally, the Company
now has 45 patents issued/allowed and 24 pending patent applications.
achievement is yet another meaningful milestone that adds a secure
foundation to build our sustainable competitive advantage. This IP allows us to protect our assets globally and advance towards commercialization,"
commented Harel Gadot, CEO, President and Chairman. "We believe our novel technology is uniquely positioned to transform
catheter-based procedures and benefit more patients globally while keeping physicians safe from radiation and reducing their physical
allowed patent pertains to a device for automatically inserting and manipulating a medical tool into and within a bodily lumen. The allowed
claims cover a compact robotic drive for driving and manipulating movement of at least one elongate surgical tool, the robotic drive
includes a housing comprising motors and a first tool-moving element driven by the motors, positioned and configured to advance or retract
the elongate surgical tool, and a second tool-moving element driven by the motors, configured to roll the elongate surgical tool about
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological platforms
provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).
Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for
patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available
pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future
financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot
Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed
by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the
Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such
as "will," "believes," "plans," "anticipates," "expects" and "estimates")
should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without
limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and/or commercialization
of potential products, including LIBERTY and SCS, the outcome of its studies to evaluate LIBERTY, SCS and other existing and future technologies,
uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting
from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading "Risk Factors" in Microbot Medical's periodic reports
filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical
disclaims any intent or obligation to update these forward-looking statements, except as required by law.